From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
The need for the type of accountability provided by order management technology has never been greater. Price Transparency legislation passed in a handful of states in 2017, including California. Additional states are working on their own bills. These laws have the potential to encourage price speculation. At the same time, the opioid epidemic has grown into a full-scale public health crisis and has placed the pharmaceutical industry under the microscope.
In this webinar, we’ll demonstrate how effective order management can limit a manufacturer’s susceptibility to price speculation and serve as a safeguard against suspicious orders of highly-regulated, controlled drugs.
Melissa O’Neal, Segment Leader, Distribution, is the presenter for Controlling Risks through Order Management: Addressing Price Transparency Laws and the Opioid Crisis.
